Bellevue Group Ag Apellis Pharmaceuticals, Inc. Transaction History
Bellevue Group Ag
- $4.39 Billion
- Q2 2025
Shares
15 transactions
Others Institutions Holding APLS
# of Institutions
319Shares Held
123MCall Options Held
3.57MPut Options Held
778K-
Avoro Capital Advisors LLC New York, NY12.2MShares$242 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$198 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$191 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$184 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT7MShares$139 Million4.3% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.18B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...